Korro Bio, Inc. (KRRO) News
Follow Korro Bio, Inc. (KRRO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Korro Bio Shares Fall 11% After Novo Nordisk Ends Collaboration
Korro Bio said Novo Nordisk terminated a research collaboration and license agreement. Korro Bio shares fell 11% to $14.88 midday Thursday, after rising about 86% year to date.
EQUITY | Nov 05, 2026, 08:02 PM UTC
M
Korro Bio Reports Zero Revenue and $0.98 Loss in Third Quarter
Korro Bio reported no collaboration revenue in the third quarter, down from $1.1 million a year earlier, while its net loss narrowed. Lower research and development costs, primarily following termination of the KRRO-110
EARNINGS | Nov 05, 2026, 12:14 PM UTC
M
Korro Bio Reports Third-Quarter Loss per Share
EQUITY | Nov 05, 2026, 12:06 PM UTC
L
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) NASDAQ:KRRO, a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of
NEWS | Sep 11, 2026, 08:11 PM UTC
L
KRRO - Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
KRRO - Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEWS | Sep 11, 2026, 08:05 PM UTC
L
Korro to Participate in Upcoming Investor Conferences
Korro to Participate in Upcoming Investor Conferences
EQUITY | Aug 27, 2026, 11:07 AM UTC
L
KRRO - Korro to Participate in Upcoming Investor Conferences
KRRO - Korro to Participate in Upcoming Investor Conferences
EQUITY | Aug 27, 2026, 11:00 AM UTC
L
Korro Bio reports inducement grant under Nasdaq Rule 5635(c)(4)
Korro Bio reports an inducement grant under Nasdaq Listing Rule 5635(c)(4); no grant size, recipient details or catalyst was supplied.
REGULATION | Aug 14, 2026, 08:05 PM UTC
L
Korro Bio Form 4: Lynx1 Capital Management LPP buys 6,684 shares
Korro Bio, Inc. files a Form 4 showing 10% owner Lynx1 Capital Management LPP purchasing 6,684 shares at $11.791 per share for a reported $78,809 total.
REGULATION | Aug 13, 2026, 02:06 PM UTC
L
KRRO - Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
KRRO - Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 06, 2026, 11:01 AM UTC
L
Korro Bio Insider Sold Shares Worth $1,542,970, According to a Recent SEC Filing
() -- Jean Francois Formela, Director, on July 02, 2026, sold 110,023 shares in Korro Bio (KRRO) for $1,542,970. Following the Form 4 filing with the SEC, Formela has control over a total of 852,861 common shares of the
REGULATION | Jul 08, 2026, 08:06 AM UTC